Multiple system atrophy is a rare, progressive neurodegenerative condition for which there is currently no cure.
Patients with idiopathic parkinsonism have reduced survival, although survival is dependent on the type and characteristics of the parkinsonian disorder.
The normal human appendix seems to contain pathogenic forms of α-synuclein, which may impact the risk for developing Parkinson disease.
Patients with both Parkinson disease and type 2 diabetes were more likely to have cardiovascular comorbidities than those with only Parkinson disease.
Participants in the RBD group had significantly worse performances on the Symbol Digit Modality Test compared with participants in the hyposmia and NMC cohorts.
Gout may be associated with a higher risk for incident PD in older adults.
The open-label safety study included patients from 3 Gocovri dyskinesia efficacy trials (N=223) and evaluated the long-term safety and tolerability of the treatment.
In order to determine the risk of PD associated with various β2‐adrenoreceptor drugs, the study authors assessed United States Medicare beneficiary data from 2009.
A greater proportion of patients with dysautonomia had supine hypertension compared with patients without dysautonomia.
Based on the data, the FDA has concluded that the drug's benefit continues to outweigh its risks for patients with hallucinations and delusions associated with Parkinson's disease psychosis.
Kinase inhibition or allele-specific targeting of mutant LRRK2 may still be a meaningful target for therapeutic development.
The FDA approval was supported by data from bioavailability studies comparing riluzole tablets and Tiglutik oral suspension.
A sensor array has the potential to identify de novo Parkinson's disease (PD) patients with high sensitivity, specificity, and accuracy values.
The studies that included neurocognitive measures demonstrated no significant difference between the use of rTMS and sham-rTMS.
No differences were observed between overground and treadmill walking with regard to stride and stance time.
The inability to compare patients with vs without tremor as well as the inclusion of patients attending a single center, which may reduce the generalizability of the findings.
Rasagiline was associated with a significant effect on survival within 6 months of treatment in an exploratory analysis.
Mutations in the LRP10 gene appear to be common in patients with inherited α-synucleinopathies.
Investigators sought to determine whether patients with moderate to advanced Parkinson disease have impaired glucose levels during an Oral Glucose Tolerance Test.
Investigators developed and evaluated a targeted sequencing approach using a panel of genes involved in movement disorders.
Children with a complex motor disorder, characterized by a combination of movement and posture abnormalities (eg, spasticity and dystonia), were enrolled.
Meige syndrome is a craniofacial dystonia characterized by involuntary muscle contractions of the jaw and around the eyes.
Across the entire cohort, the predominant motor types featured were 70% spastic, 22% dyskinetic (21% dystonic and 1% choreoathetotic), 6% hypotonic, and 2% ataxic.
The Parkinson's Foundation Prevalence Project estimates that within the next 2 years, 930,000 people in the United States will be living with the condition; that number is anticipated to rise to 1.2 million by 2030.
Researchers collected and analyzed data on age at onset, sex, family history of dystonia, and the presence of associated anatomic sites with dystonia.
Investigators sought to determine if the ECAS diagnostic screening tool is sufficiently sensitive to distinguish between progressive supranuclear palsy and Parkinson disease.
Study investigators enrolled a total of 37 patients with PD who had participated in a larger prospective, controlled exercise study.
Nuplazid, a non-dopaminergic, selective serotonin inverse agonist, targets 5-HT2A receptors that are thought to be involved in Parkinson's disease psychosis.
There is an increased rate of subsequent Parkinson disease among individuals diagnosed with type 2 diabetes mellitus.
For patients with Parkinson disease, dopamine agonist use is associated with incidence of impulse control disorders in a dose-effect relationship.
Neurology Advisor Articles
- Multiple System Atrophy: A Common Form of Atypical Parkinsonism
- Migraine Treatment in the ED: Overcoming Our Penchant for Opioids
- Oral Film Formulation of Clobazam Gets FDA Approval for LGS
- Erenumab as a Therapy for Hard to Treat Episodic Migraine
- Nusinersen May Be Effective for Short-Term Motor Function Improvements in Spinal Muscular Atrophy
- New Diagnostic Criteria for Neurosarcoidosis: What You Need to Know
- Guideline for Diagnosis and Treatment of Idiopathic Intracranial Hypertension
- Guidelines on the Use of OnabotulinumtoxinA for Chronic Migraine
- Ivy League Rule Change Linked to Fewer Concussions During NCAA Football Games
- Biomarkers of Alzheimer Disease Observed in Down Syndrome
- Ocrevus Labeling Updated With New Info on Timing of Vaccine Administration
- Approaches for Better Diagnosis of Pediatric Multiple Sclerosis
- Short Segment Sensory Nerve Stimulation Offers Potential Diagnostic Value for Ulnar Neuropathy
- Incidence of Guillain-Barré Syndrome Linked With Recent Bone, Digestive Organ Surgery
- Pharmacist-Led Effort Cuts Inappropriate Rx in Older Adults